axsomelogo-468x57.jpg
Axsome Therapeutics Reports Third Quarter 2018 Financial Results and Provides Business Update
November 09, 2018 07:00 ET | Axsome Therapeutics, Inc.
Final Phase 3 results of AXS-05 in treatment resistant depression now anticipated in 1Q 2019 Final Phase 2 results of AXS-05 in major depressive disorder anticipated around year-end 2018 Phase 2/3...
axsomelogo-468x57.jpg
Axsome Therapeutics Reports First Quarter 2018 Financial Results and Provides Business Update
May 08, 2018 07:00 ET | Axsome Therapeutics, Inc.
NEW YORK, May 08, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system...
Axsome Logo.png
Axsome Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
March 07, 2018 07:00 ET | Axsome Therapeutics, Inc.
Interim analyses of STRIDE-1 and ADVANCE-1 trials of AXS-05 anticipated in 2018 Company to host conference call today at 8:00 AM Eastern NEW YORK, March 07, 2018 (GLOBE NEWSWIRE) -- Axsome...
Axsome Logo.png
Axsome Therapeutics to Present at 2018 BIO CEO & Investor Conference
February 05, 2018 07:00 ET | Axsome Therapeutics, Inc.
NEW YORK, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Logo.png
Axsome Therapeutics Announces AXS-02 Independent Data Monitoring Committee Recommends Continuation of COAST-1 Trial and Discontinuation of CREATE-1 Trial
January 09, 2018 07:00 ET | Axsome Therapeutics, Inc.
COAST-1 is a Phase 3 trial of AXS-02 in knee osteoarthritis associated with bone marrow lesions CREATE-1 is a Phase 3 trial of AXS-02 in complex regional pain syndrome Significant reduction in bone...
Axsome Logo.png
Axsome Therapeutics to Present at Biotech Showcase 2018
December 19, 2017 07:00 ET | Axsome Therapeutics, Inc.
NEW YORK, Dec. 19, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Logo.png
Axsome Therapeutics Reports Third Quarter 2017 Financial Results
November 08, 2017 07:00 ET | Axsome Therapeutics, Inc.
NEW YORK, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Logo.png
Axsome Therapeutics to Present at Upcoming Investor Conferences
September 18, 2017 07:00 ET | Axsome Therapeutics, Inc.
NEW YORK, Sept. 18, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Logo.png
Axsome Announces CREATE-1 Interim Analysis Expected Year-End 2017
September 07, 2017 07:00 ET | Axsome Therapeutics, Inc.
NEW YORK, Sept. 07, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Logo.png
Axsome Therapeutics Reports Second Quarter 2017 Financial Results
August 09, 2017 07:00 ET | Axsome Therapeutics, Inc.
NEW YORK, Aug. 09, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...